INTRODUCTION
Sarcoidosis can affect almost any portion of the eye or surrounding tissue. Examples include uveitis, scleritis, dry eye, optic neuritis, conjunctival granuloma, or exophthalmos. Uveitis can lead to visually significant complications such as cataract, glaucoma, retinal vasculitis, vitreous opacities, and macular edema [1] .
Central nervous system involvement resulting from sarcoidosis can affect vision in a variety of ways including altering the function of cranial nerves [2] . To capture new developments in understanding sarcoidosis as it relates to eye disease, we searched the national library of medicine database using the key word, 'ocular sarcoidosis'. We selected papers published since 2015 and ignored papers written in languages other than English or reports in the form of reviews. We also included publications on the differential diagnosis of uveitis or therapeutic advances if the report related to sarcoidosis. We report on the frequency of sarcoidosis as a cause of uveitis based on surveys from a variety of countries; the application of international workshop of uveitis criteria to diagnose uveitis; novel observations on clinical features of uveitis or parameters that affect prognosis; new insights into pathogenesis or biomarkers; gene expression patterns associated with lacrimal or orbital involvement by sarcoidosis; and results with biologic therapy to treat ocular sarcoidosis.
Dry eye is arguably the most common ocular manifestation of sarcoidosis. Dryness, however, usually does not result in severe visual loss. In contrast, uveitis is arguably the most common form of ocular involvement with the potential to affect
OVERVIEW OF UVEITIS
Uveitis is the term used to describe an inflammation of the uvea which includes iris, ciliary body, and choroid. Uveitis is most commonly classified by anatomical location [anterior chamber, vitreous humor (intermediate uveitis), or choroid-retina (posterior uveitis)] of the observed inflammation using slit-lamp biomicroscopy and fundus examination. Sarcoidosis-associated uveitis can present as anterior, intermediate, posterior, or panuveitis. Frequent symptoms from uveitis include redness, eye pain, light sensitivity, vitreous floaters, and blurry vision according to the extent, severity, location, and suddenness of the onset of inflammation.
The uveitis associated with sarcoid is generally bilateral and chronic. Anterior segment examination by slit-lamp biomicroscopy may show granulomatous keratic precipitates (inflammatory cellular deposit on the posterior surface of cornea), iris nodules, iris adhesion to cornea (anterior synechiae) or lens (posterior synechiae). Chronic uveitis can lead to cataract formation, secondary glaucoma, and keratopathy. Fundus examination can reveal various degree of vitreous opacities, snow balls (aggregates of inflammatory cells in the vitreous humor posterior to the lens), and snow banks (accumulation of white exudates over the pars plana and ora serrata) in the vitreous cavity. These can be highly suggestive of granulomatous inflammation. Characteristic fundoscopic findings also include retinal periphlebitis and choroidal granuloma. Visual deterioration can be caused by media opacity (cataract and vitreous opacity), macular edema, and secondary glaucoma. The degree of anterior chamber inflammation and vitreous opacity can be assessed by standard guidelines and the treatment response can be judged also by the number of inflammatory cells in anterior chamber according to the standard guideline [3, 4] .
Conjunctival involvement is common, but is frequently ignored as most conjunctival lesions are asymptomatic. These can present as nodules, cicatricial conjunctival scarring, and granuloma. Reportedly, sarcoidosis-associated scleritis is uncommon but may present in older female patients [5] .
The lacrimal gland is a commonly affected orbital organ in sarcoidosis. Lacrimal gland inflammation which results in decreased aqueous tear production can cause keratoconjunctivitis sicca. Keratoconjunctivitis sicca in sarcoidosis patients is a different category from Sjogren's syndrome by recent classification from the American college of rheumatology and the European league against rheumatism [6] .
Neurological involvement is observed in 5-26% of sarcoidosis cases [2] . Cranial neuropathy is the most frequent neurological manifestation; facial nerve and optic nerve are the most commonly affected [2] .
Various systemic diseases can cause uveitis. The rate of sarcoidosis-associated uveitis varies with ethnicities and countries. It can account for as much as 11.4% of patients in a referral clinical based on a survey of recent reports from around the world (Table 1) [7] [8] [9] [10] [11] [12] [13] [14] [15] .
Two peaks of incidence are reported: the first in those aged 20-30 years, and the second in those aged 50-60 years [16] . Females (76%) are more likely to develop ocular involvement compared with males (24%) in a study with biopsy-proven systemic sarcoidosis [1] . Sarcoidosis is relatively rare in children but may affect childhood and cause uveitis in young age also [17] . However, most of patients previously diagnosed as early onset sarcoidosis are now considered as having Blau syndrome with de novo mutation [18] .
Sarcoidosis can be included on the differential diagnosis of almost any presentation of uveitis. Diagnostic criteria for sarcoidosis-associated uveitis have been proposed at first international workshop on ocular sarcoidosis (IWOS) in 2009 ( clinical findings consistent with sarcoidosis by IWOS criteria [19] . Second, evidence of noncaseating granulomas must be demonstrated histologically on a tissue biopsy. Third, other causes of granulomatous inflammation must be excluded such as tuberculosis or syphilis. Many patients with clinical features of ocular sarcoidosis are unable to undergo biopsy or do not have an appropriate site for biopsy. In these cases, a diagnosis of probable or presumed ocular sarcoidosis is made based on clinical features, laboratory findings and chest imaging results according to the IWOS criteria [19] . The IWOS criteria have been recently validated in several countries and shown high reliability for the clinical diagnosis of ocular sarcoidosis [20, 21] . However, the criteria have some limitations. First, abnormal liver Ophthalmologic tools for diagnostic imaging include fundus photo camera, fluorescein angiography, fundus autofluorescence (FAF), and optical coherence tomography (OCT). These technologies are evolving rapidly and changing how patients with uveitis are evaluated.
Fundus photography for the uveitis patient with vitreous opacities may be helpful for the documentation and objective future comparisons. Ultrawide field retinal imaging has gained popularity and can provide a wider view of approximately 2008, which covers 82% of the retina in a single image, whereas conventional fundus photography provides a 308 field of view (Fig. 1a) [22] . This allows for documentation and comparison of peripheral retinal findings. The area of apparent fluorescein leakage because of retinal vasculitis can be also greater and more diagnostic with wide field images than in conventional nine-field montage images (Fig. 2) [23] . FAF has proven to be a valuable tool for the detection of subclinical retinal pigment epithelium changes in chorioretinal pathologies which are not seen in fundoscopic examination and usual color fundus photography. FAF may become an essential tool to detect subtle inflammatory change and monitor treatment response in uveitis patient with chorioretinal lesions (Fig. 3 ) [24] .
Severity of macular edema correlates with severity of ocular inflammation and loss of visual acuity [25] . Macular edema can be assessed and monitored with OCT (Fig. 4) . The integrity of the photoreceptor inner segment and outer segment junction and external limiting membrane on OCT may predict functional outcome (visual acuity, central distortions, and scotomas) following treatment of the macular edema [26] . OCT images can detect microstructural changes of retina and choroid in a noninvasive manner. This enables detection of subclinical disease activity and monitoring of patients with uveitic macular edema.
Sarcoidosis can affect ocular and periocular structures with variable rate depending on countries and ethnicities. One report from Serbia with 88 biopsy-proven sarcoidosis showed 32 patients (36.4% of all) manifested ocular sarcoidosis [1] . Posterior uveitis was the most common (15.9%), followed by neuroophthalmologic manifestations (9.1%), conjunctival lesions (7.9%), panuveitis (5.7%), eyelid skin lesions (2.3%), orbital inflammation (2.3%), anterior uveitis (2.3%), and intermediate uveitis (1.1%). Complications included cataract (20.4%), glaucoma (5.7%), cystoid macular edema (3.4%), epiretinal membrane formation (4.5%); macular atrophy (2.3%), and choroidal neovascularization (1.1%). Binocular visual impairment was present in one patient (1.1%), because of complications of posterior uveitis (macular scars). In constrast, another study from Serbia with 55 ocular sarcoidosis patients reported that the most frequent manifestation was anterior uveitis (64.6%). Macular edema and periphlebitis associated with periarteritis were frequently observed [25] . One retrospective study with 83 cases of biopsy-proven sarcoidosis uveitis from France showed that 52 out of 83 patients initially presented with isolated sarcoid uveitis, whereas 31 out of 83 patients had original systemic sarcoidosis in addition to ocular involvement [27] . This study showed a favorable visual outcome for sarcoidosis uveitis. In total, 60.2% of all patients had complete visual recovery and 89.2% retrieved best-corrected visual acuity (BCVA) more than 20/50 in both eyes. A unilateral loss of BCVA of worse than 20/200 was documented in only two patients. There were no patients with bilateral severe visual impairment or blindness. Factors related with a poor visual prognosis (BCVA 20/50) were chronic macular edema and persistent ocular inflammation. Sarcoidosis patients with ocular involvement needed systemic therapy more frequently compared with isolated ocular sarcoidosis. Interestingly, visual outcome was better in systemic sarcoidosis with ocular involvement patients. This result might be because more systemic treatment was undertaken in systemic sarcoidosis.
There were some recent prognostic features regarding ocular sarcoidosis. To date, there were few dedicated investigations of risk factors for ocular sarcoidosis. Recently, cigarette smoking was considered as a risk factor for development of ocular sarcoidosis in a retrospective study with 109 patients [28 & ]. One retrospective study of 3364 veteran patients with sarcoidosis reported that ocular inflammation had significantly lower 1-year all-cause mortality than those without ocular inflammation [29 & ].
DIAGNOSIS OF OCULAR SARCOIDOSIS
Sarcoidosis can be included on the differential diagnosis of almost any presentation of uveitis. A chest X-ray is the best and easiest screening tool for the diagnosis of sarcoidosis, because most of patients with sarcoidosis have pulmonary involvement. One of the main diseases in the differential diagnosis is tuberculosis which also causes pulmonary changes. Babu et al. [30] showed hilar lymphadenopathy and fissural nodules were significantly more common in ocular sarcoidosis patients compared with ocular tuberculosis on high-resolution chest computerized tomography.
Recently published articles have shown that there were newly investigated laboratory findings helping diagnose uveitis associated with sarcoidosis [31] . Gundlach et al. [32 & ] showed that an elevated level of soluble interleukin-2 receptor suggests sarcoidosis with uveitis more convincingly than angiotensin converting enzyme (ACE), making soluble interleukin-2 receptor a more effective marker for sarcoidosis than ACE or chest X-ray in uveitis patients. Jones et al. [33 & ] suggested that significant lymphopenia (<1.0 Â 10 9 /l) is an independent predictor of sarcoidosis in new patients presenting with sarcoidosis-associated uveitis in a large (n ¼ 129) retrospective study.
Newly developed techniques have been investigated to show specific findings for uveitis. These findings might prove helpful for differential diagnosis for a certain type of uveitis in the future. Enhanced depth imaging OCT is suitable to visualize choroidal granulomas and to describe their characteristics [34] . OCT angiography is the most advanced technology which allows visualization of microvascular changes in superficial and deep www.co-pulmonarymedicine.comlayer in retina. Visual prognosis and disease course can be assessed and monitored by quantifying retinal capillary changes [35] . Rose-Nussbaumer et al. noninvasively evaluated the characteristic findings of inflammatory cells in the anterior chamber using OCT, inflammatory cells of sarcoidosis uveitis showed a predominantly mononuclear pattern. This technique may become a useful adjunct to guide the diagnosis and treatment [36] .
In limited cases, vitrectomy can be done and vitreous samples can be obtained for diagnostic analysis. Masaru et al. showed that high-mobility group box-1, which is secreted by activated leukocytes and acts as a primary inflammatory cytokine was detected in the vitreous of 23 of 24 patients (95.8%) with ocular sarcoidosis and the level of high-mobility group box was high as 52.5 ng/ml in ocular sarcoidosis compared to proliferative diabetic retinopathy patients (85.2%, 9.84 ng/ml), and epiretinal membrane patients (66.7%, 6.99 ng/ml) [37 & ]. The authors showed it is associated with vitreous levels of Th1 and regulatory T-related cytokines, but not with inflammatory or Th17-related cytokines. These investigations suggest that cytopathological examination of vitreous samples may contribute to the diagnosis of intraocular sarcoidosis. Interestingly, Goto et al. [38 & ] suggested Propionibacterium acne as a possible pathogen of granuloma in ocular sarcoidosis patients by showing this organism in a removed epiretinal membrane.
Siasos et al. reported that ocular involvement in sarcoidosis patients was associated with impaired endothelial function (estimated the flow-mediated dilation in the brachial artery) and increased arterial stiffness (measured carotid-femoral pulse wave velocity) [39] . These results strengthened the vascular theory which considers uveitis a consequence of vascular dysfunction in sarcoidosis patients and revealed a possible clinical importance of the use of endothelial function tests. Ocular inflammation (chorioretinal lesions) can be a marker of microcirculatory damage in sarcoidosis patients and choroidal involvement is associated with an increased risk of cardiac disease.
Sarcoidosis can affect various components of the orbit including the lacrimal gland or adipose tissue. Using formalin-fixed biopsies provided by an international consortium, we have characterized the pattern of gene expression in this tissue. Our observations show that distinct diagnoses such as sarcoidosis, thyroid-associated eye disease, or granulomatosis with polyangiitis generally have unique and recognizable patterns of gene expression [40 & ]. Furthermore, mRNA transcripts which are either up or downregulated in lacrimal gland or orbital adipose tissue are often similarly altered in whole blood [41] . This suggests the possibility that the measurement of gene expression in peripheral blood could ultimately become an accurate diagnostic modality for sarcoidosis or for identifying the cause of orbital inflammatory disease. Pathway analsysis suggests that transcripts which are upregulated in blood, orbital fat, and lacrimal gland from patients with sarcoidosis are frequently regulated by the transcription factors, interferon response factors 1 and 2, and nuclear factor kB [42 & ].
MANAGEMENT OF OCULAR SARCOIDOSIS
The primary purposes for the management of ocular sarcoidosis are to restore vision and to prevent complications from inflammation-related ocular structural changes.
Corticosteroids
The first-line treatment for ocular sarcoidosis is corticosteroids. Anterior uveitis is treated with topical corticosteroids with/without cycloplegics to prevent synechiae. About 0.05% difluprednate is relatively new and more potent topical medication. Its potency is at least double prednisolone acetate 1% (the most popular topical corticosteroid used for uveitis therapy in the United States) for the treatment of anterior uveitis [43] . Regional corticosteroid injections and implants can be considered in posterior uveitis or cases of poor responders to topical steroids. Those include subconjunctival, periocular or subtenon injection, and intravitreal injections. A biodegradable intraocular implant containing dexamethasone given through the pars plana with a 22-gauge applicator has been approved for the treatment of uveitis involving the posterior segment of the eye. A single dexamethasone implant was effective in improving vision and macular edema in the majority of the patients with noninfectious causes of uveitis. However, recurrence of macular edema was observed in approximately 65% of the patients at 6 months [44] . A sustained-release fluocinolone acetonide implant has been approved in the United States for chronic noninfectious posterior uveitis since 2005. All patients who receive this implant eventually require cataract surgery and one-third require filtering surgery to control glaucoma not controlled by topical medications [45] . The multicenter uveitis steroid treatment trial has recently compared the effectiveness of systemic corticosteroids in combination with immunosuppression versus the fluocinolone acetonide implant for noninfectious uveitis. This study suggests that implant therapy is valuable for patients with uveitis who do not require systemic treatment for nonocular indications [46] .
Systemic immunosuppressive agents
These agents are indicated in corticosteroiddependent or intolerant cases as a steroid sparing purpose. Commonly used antimetabolite agents for long-term control of systemic and ocular inflammation include methotrexate, mycophenolate mofetil, or azathioprine. Among T-cell inhibitors, cyclosporine and tacrolimus, have been shown efficacy in decreasing inflammation in uveitis. However, voclosporin failed to meet its primary endpoint in the majority of clinical trials [47] . Subconjunctival/intravitreal sirolimus has demonstrated dose-dependent benefit (the highest dose was not as effective as a lower dose used in the trial) [48] but it is not an food and drug administration-approved option at the time of this writing.
Biologic agents
Patients who are refractory to steroid-sparing agents often benefit from biologics. Interferons showed possible beneficial for the treatment of macular edema associated with uveitis [47] . Interferons, however, can also cause systemic granulomatous disease. Biologic agents studied for the treatment of uveitis related to sarcoidosis are tumor necrosis factor-a inhibitors, including infliximab, adalimumab, etanercept, golimumab, and certolizumab. Among those, etanercept showed no significant difference between etanercept and placebo groups [47] . Among tumor necrosis factor-a inhibitors, adalimumab, is the only systemic noncorticosteroid agent which has been approved by the US food and drug administration for the treatment of noninfectious uveitis. Two successful trials with adalimumab for noninfectious, intermediate, posterior, or panuveitis uveitis have been reported. Jaffe et al. [49 && ] reported the result of a multinational phase 3 trial (VISUAL I) involved adults who had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite having received prednisone treatment for 2 or more weeks. This study included 217 patients, 16 patients were associated with sarcoidosis as underlying cause. In this trial, adalimumab was found to be associated with a lower risk of uveitic flare or visual impairment and it demonstrated a steroid sparing effect. Nguyen et al. [50 && ] published another multicenter, double-masked, randomized, placebo-controlled phase 3 trial (VISUAL II) with adalimumab. This study included 229 patients (aged !18 years) with inactive, noninfectious intermediate, posterior, or panuveitis controlled by 10-35 mg/day of prednisone. Patients were randomly assigned with 1 : 1 ratio to placebo or adalimumab. From week 2, all patients underwent a mandatory prednisone taper to 0 mg by week 19. In total, 32 patients had sarcoidosis-associated uveitis. This study showed that adalimumab significantly lowered the risk of uveitic flare or loss of visual acuity on corticosteroid withdrawal with inactive uveitis patients. Adalimumab also showed the efficacy for pediatric patients with anterior uveitis [51] . Riancho-Zarrabeitia et al. [52] showed the effectiveness of adalimumab in refractory sarcoidosis-associated uveitis with 17 patients. Overall, adalimumab can be a next treatment for refractory uveitis cases on antimetabolites or T-cell inhibitors and this does not mean only for sarcoidosis-associated uveitis. Owing to limited longterm safety and efficacy data, biologic therapy is reserved as secondary or tertiary treatment of uveitis associated with sarcoidosis.
Surgery
Surgical interventions may be needed in cases resistant to medical treatment to remove media opacity such as vitreous opacity and cataract. Surgery can exacerbate ocular inflammation, microincision vitrectomy surgery using wide-viewing system is minimal invasive and showed favorable outcome for complicated ocular sarcoidosis cases without aggravation of ocular inflammation by surgical stress [53] .
CONCLUSION
The diagnosis of ocular sarcoidosis is important for not only the ophthalmologist but also the rheumatologist and pulmonologist. Traditional laboratory, radiologic and pathologic findings are crucial and should be evaluated initially. There are no standardized therapeutic guidelines for ocular sarcoidosis. Traditionally used systemic immunosuppressive agents should be considered as primary steroid sparing agents. In refractory cases, adalimumab is now a therapeutic option.
